attent shift analyst
share like pressur maintain underweight ew share indic
lower after-hour trade expect stock open wednesday
reason edward report sale fell short consensu expect
mainli due lighter transcathet heart valv therapi thvt sale
manag temper thvt expect remaind year
net/net noth quarter chang view stock maintain
underweight rate would buyer weak
temper thvt expect driven two factor like carry-
first edward expect on-going suppli constraint cardioband
trim roughli transcathet mitral tricuspid therapi tmtt
forecast suppli constraint expect continu progress
improv second edward plan control roll-out strategi
sapien ultra system europ ensur proper train procedur success
sapien ultra expect receiv ce mark eu approv sometim
control roll-out could also moder outlook assum boston
scientif exercis right enjoin sapien ultra germani
what next analyst meet decemb analyst meet expect
edward provid thorough pipelin updat first cut
guidanc believ consensu sale expect like moder
follow quarter miss mgmt temper expect think
consensu ep like high expect invest spend tmtt
valuat risk thesi weve rais ep maintain
ep pt ep risk includ
regulatori action patent litig outcom reimburs chang
ew quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
sale street higher-than-expect critic sale
off-set weaker transcathet surgic heart valv sale
underli sale ep street/our
estim compani guidanc rang
upsid mainli function better gross margin well slightli
impli like lower-than-expect
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
sale product categori
gross margin improv result favor product mix
absenc hurrican maria relat expens
critic sale better-than-expect underli sale growth
led hemospher new group purchas organ contract win
impact tax rate employe stock-bas compens better
expect contribut ep beat
world-wide transcathet valv therapi thvt sale came expect
manag also temper expect year expect sale remain
ytd area versu high end reflect limit
contribut cardioband well control roll-out sapien ultra
manag reiter total sale guidanc higher end
thvt sale expect temper critic sale ahead
adjust ep guidanc reiter given beat impli lower
sale underli basi underli growth divis
transcathet heart valv therapi structur heart critic
gross margin y/i due product mix absenc
hurrican cost year ago quarter
sg sale y/i manag comment margin would
lower exclud impact consign convers
 sale y/i edward continu invest pipelin
adjust tax rate y/i low end expect
stock-bas compens contribut benefit
higher expect contribut ep beat
adjust ep street estim
edward expect sale versu street pre-releas
ep versu street pre-releas
edward reiter full year guidanc rang expect sale
higher end rang adjust ep time
earn releas street respect
actual million salesrptdex fx/org transcathet heart heart barclay edward lifesci corp
expect
edward success turn transcathet heart valv therapi thvt
stock gener trade along updat regard context given shortfal
sale rel consensu expect manag moder view
ahead expect stock pressur wednesday trade
edward thvt sale total million quarter reflect underli
growth howev sale streetaccount consensu expect
million estim million manag moder outlook
remaind year edward expect full year sale growth remain
area year-to-d perform due limit contribut
cardioband expect million versu prior expect
million revis roll-out strategi next-gener tavr devicesapien ultra
reflect edward desir ensur proper train procedur success
relat potenti injunct manag previous expect thvt sale
high end rang
asid boston scientif report result wednesday may
comment recent german court rule favor whether compani intend
post bond prompt injunct sapien ultra product germani edward
expect receiv ce mark eu approv day edward plan appeal
court rule
transcathet aortic valv sale million
transcathet mitral tricuspid valv tmtt updat
manag provid select updat mitral product pipelin expect
comprehens review compani transcathet mitral tricuspid therapi
tmtt upcom investor day decemb
cardioband sale contribut limit due on-going suppli constraint
edward acquir cardioband transcathet mitral/tricuspid annuloplasti ring
januari valtech acquisit valtech privat held compani base israel
begin edward began integr cardioband suppli chain
edward qualiti system impact product suppli moreov edward start
priorit suppli clinic trial manag initi believ sale would ramp-up
million per quarter level achiev million howev
longer expect possibl expect sale similar around
million would put full year sale around million level firm near-term
suppli scale long-term volum expect manag announc
intent transfer manufactur cardioband legaci valtech israel site
edward manufactur locat believ long-term resolv
issu nearer term product suppli constraint like persist
pascal european launch still track us pivot trial approv
edward reiter time european launch pascal system though
would provid color year launch would like take place
clasp ce mark studi current underway would expect see data read
studi would suggest launch like
manag announc approv clasp pivot trial studi
pascal devic patient primari degen mitral regurgit studi
enrol patient deem inoper surgeri center patient
random versu abbott mitraclip edward plan mr grade reduct
primari endpoint major advers clinic event mace secondari endpoint
expect compani provid commentari around timelin investor day
view like late like fda approv
edward reiter sale ep guidanc rang despit sale miss
edward continu expect sale higher end rang billion
compar pre-releas street billion previous discuss
edward moder outlook transcathet valv rais expect
critic sale said explicit sale guidanc rang million
place pre-releas street estim million upper end rang thu
would surpris see full year estim move slightli reflect
miss estim perhap closer mid-point guidanc rang continu
project sale billion estim larg unchang
edward expect ep rang compar pre-releas
street estim edward explicit ep guidanc
pre-releas ep estim thu ep beat street
estim like move lower rang guidanc net/net would
anticip street estim remain fairli even pre-releas estim
weve updat model expect ep versu prior estim
expect analyst day pipelin updat
analyst meet expect edward provid thorough pipelin updat
first cut guidanc
believ consensu sale expect like moder follow
quarter sale miss temper expect pre-releas consensu
estim impli y/i growth seem littl high us given year-to-d
perform fx rate like headwind tmtt product suppli
constraint tavr competit ahead forecast sale growth
report basi underli basi model assum transcathet heart
valv therapi thvt sale growth moder roughli
reflect combin deceler underli tavr sale growth due greater
competit contribut tmtt sale rang million forecast
underli sale growth surgic heart valv therapi consist
expect forecast underli sale growth critic
moder year project increas take foreign exchang rate
chang consider arriv report sale million
consensu result estim million base result
commentari would surpris see street estim move lower closer
estim
believ consensu ep expect could remain around releas
estim given edward reiter ep expect year
howev believ estim may high given view edward like
invest next year tmtt limit amount oper margin expans ep
estim impli nearli ep growth level
abbrevi model figur pleas contact us youd like receiv full model
abbrevi incom statement million except per share data
incom statementtranscathet heart oper inc inc barclay edward lifesci corp
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
